You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 285 No. 14, April 11, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Contempo Updates: Linking Evidence and Experience
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Melanoma
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Primary Cutaneous Melanoma

Matthew H. Kanzler, MD; Serena Mraz-Gernhard, MD

JAMA. 2001;285:1819-1821.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With a lack of scientific data, standard of care for treatment of patients with melanoma at the beginning of the 20th century called for extensive mutilating surgery and/or local amputation of involved body areas. In the mid-1900s, aggressive lymph node dissections were popular in an attempt to control metastatic disease despite the lack of scientific data that such procedures did, indeed, affect the survival of patients with melanoma. The treatment of melanoma has changed significantly in the intervening years, and can now be guided by data regarding clinical outcomes. The purpose of this review is to present clinicians with an evidence-based summary of the current literature regarding therapy for primary cutaneous melanoma.

Surgical Margins

The surgical approach to the suspect melanocytic lesion is a 2-step process. The first goal is to establish the diagnosis and obtain microstaging (ie, to determine the tumor thickness and assess . . . [Full Text of this Article]

Author Affiliations: Division of Dermatology, Santa Clara Valley Medical Center, San Jose, Calif (Dr Kanzler) and Department of Dermatology, Stanford University School of Medicine (Drs Kanzler and Mraz-Gernhard), Stanford, Calif.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Depth of Excision of Melanomas
Steven D. Macht, Matthew H. Kanzler, and Serena Mraz-Gernhard
JAMA. 2001;286(2):167-168.
EXTRACT | FULL TEXT  

RELATED ARTICLE

April 11, 2001
JAMA. 2001;285(14):1903-1904.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Variation in the Diagnosis, Treatment, and Management of Melanoma In Situ: A Survey of US Dermatologists
Charles et al.
Arch Dermatol 2005;141:723-729.
ABSTRACT | FULL TEXT  

Depth of Excision of Melanomas
Macht et al.
JAMA 2001;286:167-168.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.